Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment.

Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1020-4. doi: 10.1167/iovs.08-2654. Epub 2008 Oct 24.

PMID:
18952925
2.

Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.

Jockovich ME, Bajenaru ML, Piña Y, Suarez F, Feuer W, Fini ME, Murray TG.

Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2476-82.

PMID:
17525173
3.

Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature.

Piña Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, Jockovich ME.

Ophthalmic Res. 2009;41(3):160-9. doi: 10.1159/000209670. Epub 2009 Mar 26.

4.

Heterogeneous tumor vasculature in retinoblastoma: implications for vessel targeting therapy.

Jockovich ME, Piña Y, Alegret A, Cebulla C, Feuer W, Murray TG.

Retina. 2008 Mar;28(3 Suppl):S81-6. doi: 10.1097/IAE.0b013e318150d6f0. Erratum in: Retina. 2009 Jan;29(1):127.

PMID:
18317352
5.

Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Piña Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2671-7. doi: 10.1167/iovs.09-4255. Epub 2010 Jan 6.

6.

Increased hypoxia following vessel targeting in a murine model of retinoblastoma.

Boutrid H, Piña Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG.

Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5537-43. doi: 10.1167/iovs.09-3702. Epub 2009 Jul 2.

PMID:
19578014
7.

Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.

Jockovich ME, Suarez F, Alegret A, Piña Y, Hayden B, Cebulla C, Feuer W, Murray TG.

Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5371-6.

PMID:
18055783
8.

Cancer stem cell characteristics in retinoblastoma.

Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F.

Mol Vis. 2005 Sep 12;11:729-37.

9.

Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate.

Bajenaru ML, Piña Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castaño ME.

Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-4. doi: 10.1167/iovs.09-4500. Epub 2010 Jan 27.

10.

Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma.

Escalona-Benz E, Jockovich ME, Murray TG, Hayden B, Hernandez E, Feuer W, Windle JJ.

Invest Ophthalmol Vis Sci. 2005 Jan;46(1):8-11.

PMID:
15623747
11.

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T.

Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb.

12.

[A new orthotopic retinoblastoma model expressing green fluorescent protein].

Wang XL, Xu P, Wang F, Zhao XF, Xue YH, Huang Q.

Zhonghua Yan Ke Za Zhi. 2004 Apr;40(4):225-8. Chinese.

PMID:
15268827
13.

Higher vessel densities in retinoblastoma with local invasive growth and metastasis.

Rössler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, Schüler A, Bornfeld N, Schilling H.

Am J Pathol. 2004 Feb;164(2):391-4.

14.

Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma.

Landreville S, Ma D, Wu J, Harbour JW.

Curr Eye Res. 2010 May;35(5):435-9. doi: 10.3109/02713680903509428.

PMID:
20450257
15.

The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties.

Pajovic S, Corson TW, Spencer C, Dimaras H, Orlic-Milacic M, Marchong MN, To KH, Thériault B, Auspitz M, Gallie BL.

Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7618-24. doi: 10.1167/iovs.11-7989.

16.

Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry.

Balla MM, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R.

Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1506-14. doi: 10.1167/iovs.08-2356. Epub 2008 Nov 21.

PMID:
19029022
17.

Embryonic retinal tumors in SV40 T-Ag transgenic mice contain CD133+ tumor-initiating cells.

Wadhwa L, Bond WS, Perlaky L, Overbeek PA, Hurwitz MY, Chévez-Barrios P, Hurwitz RL.

Invest Ophthalmol Vis Sci. 2012 Jun 8;53(7):3454-62. doi: 10.1167/iovs.12-9549.

18.

Expression of p63 and p73 in retinoblastoma: a clinicopathological correlation study.

Adithi M, Nalini V, Kandalam M, Krishnakumar S.

Exp Eye Res. 2008 Oct;87(4):312-8. doi: 10.1016/j.exer.2008.06.010. Epub 2008 Jun 21.

PMID:
18619959
19.

Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Pina Y, Clarke J, Koru-Sengul T, Scott WK, Nathanson L, Schefler AC, Murray TG.

Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5359-68. doi: 10.1167/iovs.10-6321.

20.

Histopathological features and P-glycoprotein expression in retinoblastoma.

Filho JP, Correa ZM, Odashiro AN, Coutinho AB, Martins MC, Erwenne CM, Burnier MN Jr.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3478-83.

PMID:
16186322
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk